Pharmacophore

ISSN-2229-5402

Journal home page: http://www.pharmacophorejournal.com



VACCINATION STATUS AMONG COVID-19-POSITIVE CASES ADMITTED IN ISOLATION CENTERS

Amel Awadelkariem Atalfadil¹, Musa Mohamed Khair¹, Sufian Khalid Mohamed², Mohamed Osman Elamin^{3*}, Wahaj Anwar Khan³, Hatim Abdullah Natto³, Hatim Matooq Badri³, Ahmad Salah Alkathiri³, Abdullah Alzhrani³, Mohamed Alharbi³

- 1. Faculty of Medicine, University of Khartoum, Sudan.
- 2. Faculty of Medicine, Nile Valley University, Sudan.
- 3. Faculty of Public Health and Health Informatics, Umm Al-Qura University, KSA.

ARTICLE INFO

Received: 28 Sep 2023 Received in revised form: 28 Jan 2024 Accepted: 04 Feb 2024 Available online:

28 Feb 2024

Keywords: COVID-19, Pandemic, Patients, Isolation centers, Vaccination

ABSTRACT

This study aimed to study the vaccination status among Coronavirus disease 2019 (COVID-19)-positive cases admitted in isolation centers in Sudan. This is an analytical, cross-sectional, hospital-based study. It was conducted in isolation centers from January to June 2022. An organized, structured, and pretested questionnaire was used in this study (n = 297). The majority of the study participants were aged more than 60 years (71%), most of the study participants were males (58.7%), and the majority of the participants were residents in rural areas (52.7%). Most participants had COVID-19 symptoms for 1 to 2 weeks (81.7%), and only 7 (2.3%) were vaccinated. This study found that those vaccinated were more likely to be improved and discharged. In addition, this study found that lack of oxygen and mechanical ventilation was associated with deaths. Vaccination is considered an important tool to reduce the risk of many infectious diseases. The current study found that vaccination against COVID-19 is effective and can reduce the risk of COVID-19 infection. Based on that, more people should consider taking the vaccine.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms.

To Cite This Article: Atalfadil AA, Khair MM, Mohamed SK, Elamin MO, Khan WA, Natto HA, et al. Vaccination Status Among COVID-19-Positive Cases Admitted in Isolation Centers. Pharmacophore. 2024;15(1):36-40. https://doi.org/10.51847/3zNNycWWrv

Introduction

The coronavirus disease 19 global pandemic has caused over 216 million cases and 4,50 million deaths as of 30 August 2021. The severe acute respiratory syndrome (SARS) coronavirus 2 belongs to the family Coronavirdae. It is known to be responsible for the outbreak of acute atypical respiratory infections that can be fatal in vulnerable individuals. Infection is transmitted through the inhalation of droplets and interaction with contaminated surfaces [1].

Several coronavirus vaccines have been fast-tracked to control the pandemic. Theusage of immune adjuvants that can boost immunological memory has come to the surface. This is important given the rate of failure of seroconversion and reinfection after COVID-19 infection, which could make vaccine rate and response debatable. Vaccines can stop most people from getting sick with covid 19, but noteveryone [2].

An efficacious vaccine is essential to prevent further morbidity and mortality. Vaccination can be regarded as one of the most effective weapons to eliminate the pandemic, but the impact of the vaccine on daily COVID-19 new cases and deaths is unclear. Scientists have claimed that the development of effective vaccines and rapid vaccination programs are the foremost measures to manage the COVID-19 pandemic [3].

The goal of the vaccine is to protect humans against severe COVID-19 infection and death. It offers strong protection, but that protection takes time to build.

All required doses of the vaccine must be taken to build full immunity, and it takes 2_3 weeks from the final vaccination to be fully effective. Even after someone takes all of therecommended doses and waits a few weeks for immunity to build up, there is still a chance they can get infected [3].

Corresponding Author: Mohamed Osman Elamin; Faculty of Public Health and Health Informatics, Umm Al-Qura University, KSA. Email: mohsm71@yahoo.com.

Pharmacophore, 15(1) 2024, Pages 36-40

This study aimed to evaluate the correlation between the vaccine and newly confirmed ases and deaths of COVID-19 in the River Nile state, Sudan.

Materials and Methods

Study Design

This is an analytical, cross-sectional, hospital-based study.

Study Area

The study was conducted in isolation centers at River Nile State hospitals.

Study Duration

Data were collected over a month from January to June 2022.

Study Population

The study population of this study was the COVID-19 patients who were admitted to an isolation center in a hospital in the River Nile state.

Inclusion Criteria

- · Patients who are 18 years and older
- Confirmed to have COVID-19 infection
- · Admitted within the study period
- · Accept participation in a study

Exclusion Criteria

Patients who were admitted to isolation centers outside the River Nile state.

Sampling

The total coverage method was used in this study.

Data Collection

An organized, structured, and pretested questionnaire was used in this study. Datawere collected by the researcher. Adult patients who confirmed COVID-19 infection were included in the study; a structured questionnaire.

Data Analysis

Data were reviewed, ordered, and then entered into an Excel spreadsheet. Data were analyzed using Statistical Package for Social Sciences (SPSS) Windows version 26. The appropriate statistical tests were used (t-test or One-Way ANOVA). Descriptive data were presented in tables and/or figures.

Ethical Consideration

Ethical approval was obtained from the Sudan Medical Specialization Board (SMSB), the ethical committee at the research unit EDC, the Ministry of Health, and the administration of the targeted hospitals.

Written informed consent was taken from administrators of the hospital and all patients before participating in the study.

Results and Discussion

Comorbidities

Hypertension was the most common comorbid condition (96, 32%), followed byDM (69, 23%) and others (Table 1).

Table 1. Comorbid conditions among the study participants.

Comorbidities		Number	Percentage
A 41	Yes	12	4.0
Asthma —	No	288	96.0
Hymoutoncion (HTM)	Yes	96	32.0
Hypertension(HTN) —	No	204	68.0
D: 1 4 PF (DM)	Yes	69	23.0
Diabetes mellitus(DM) —	No	12 288 96 204	77.0
Indiania haratiana (IIID)	Yes	15	5.0
Ischemic heartdisease (IHD)	No	285	95.0

Pharmacophore, 15(1) 2024, Pages 36-40

Vaccination Status

In this study, only 7 (2.3%) of the participants were vaccinated. Out of 7 vaccinated participants, 3 received Johnson and Johnson vaccination (**Table 2**).

Table 2. Vaccination status of the study participants.

Vaccination status		Number	Percentage
Vaccination status	Vaccinated	7	2.3
	Not vaccinated	293	97.7
	Not mentioned	2	28.6
T	AstraZeneca	1	14.3
Type of vaccine	Johnson	3	42.9
	Astrazeneca and Johnson	1	14.3
N	One	4	57.1
Number of doses -	Two	3	42.9
Duration sincelast dose	1-2wees	4	57.1
	>2weeks	3	42.9

Complications

In this study, 76 (25%) of the participants developed complications (**Figure 1**). The complications found were not associated with vaccinations, and they were due to hypertension and diabetes mellitus.




Figure 1. Presence of complications among the study participants.

Associations

Association Between Vaccination Status and Presence of Complications

This study found no association between vaccination status and the presence of complications (Table 3).

Table 3. Association between vaccination status and the presence of complicationsamong the study participants.

Vaccination		Complications	
		Yes	No
vaccinationstatus —	Yes	2	5
vaccinationstatus —	No	219	74
P-value		0.842	

This study found an association between vaccination status and the outcome of COVID-19, where those vaccinated are more likely to be improved and discharged (P-value = 0.021)

Association Between the Need for Oxygen Therapy and the Outcome

This study found that the need for oxygen is associated with death (p-value =0.039) (**Table 4**).

Pharmacophore, 15(1) 2024, Pages 36-40

Table 4. Association between the need for oxygen and outcome of COVID-19among the study participants.

Need for oxygen		Outcome	
		Improved anddischarged	Death
Need foroxygen therapy —	Yes	165	109
	No	21	5
P-value		0.039	

Association Between the Need for Mechanical Ventilation and the Outcome

This study demonstrated that the need for mechanical ventilation is associated withdeath (p-value = 0.004) (Table 5).

Table 5. Association between the need for mechanical ventilation and outcome of COVID-19 among the study participants.

mechanical ventilation		Outcome	
mechanicai ventuation		Improved and discharged Death	
Need for mechanical ventilation	Yes	0	5
	No	186	109
P-value		0.004	

This study aims to study the vaccination status among COVID-19-positive cases admitted in isolation centers in River Nile State. Most participants had COVID-19 symptoms for 1 to 2 weeks (81.7%), 15% reported a history of a similar condition, and 91.7% did not report a family history of a similar condition. In this study, only 7 (2.3%) of the participants were vaccinated. Out of 7 vaccinated participants, 3 received Johnson and Johnson vaccination. Most of the participants required oxygen (91%), and only 5 (1.7%) required mechanical ventilation. This study found an association between vaccination status and the outcome of COVID-19, where those vaccinated are significantly more likely to be improved and discharged. In addition, this study found that an altered consciousness level, and need for oxygen or mechanical ventilation are significantly associated with death. The complications found were not associated with vaccinations. They were due to hypertension and diabetes mellitus. The main symptoms of COVID-19 among participants of this study were cough, breathlessness, fever, undue fatigue, headache, nausea and vomiting.

Hypertension was the most common comorbid condition (96, 32%) in this study, followed by DM (69, 23%) and others. In this study, only 7 (2.3%) of the participants were vaccinated. This finding is different from a study conducted by J. Muthukrishnan *et al.* among patients of COVID-19 in India, in which 39% of the participants were vaccinated [4]. This difference could be due to the socio-demographic characteristics of participants in each study, and due to the difference in the economic status of each country.

This study found no association between vaccination status and the presence of complications. This finding differs from another study conducted by Nick Andrews *et al.* which found that COVID-19 vaccinations effectively reduce the risk of COVID-19-related complications [5].

This study found an association between the conscious state and the outcome of COVID-19, in which having an altered conscious state is associated with death (p-value <0.001). This finding is comparable to another study conducted by Boehme *et al.* found that impaired consciousness, such as coma, isfrequent in patients suffering from severe COVID-19 disease [6].

This study found an association between vaccination status and the outcome of COVID-19, where those vaccinated are more likely to be improved and discharged (P-value = 0.021). This finding is consistent with anotherstudy conducted by Moghadas *et al.* which found that COVID-19 vaccination can reduce ICU admission and the overall mortality rate of COVID-19 [7]. Moreover, this finding is similar to another study by Bernal *et al.* where there is a 51% lower risk of death compared to unvaccinated people [8]. These findings emphasize the importance of COVID-19 vaccination and point toward the coverage of a larger population with the vaccine.

This study found a significant association between the need for mechanical ventilation and outcome, where the need for mechanical ventilation is associated with death (p-value = 0.004). Using mechanical ventilators among COVID-19 patients is associated with severe disease. Data suggest that patients with COVID-19-associated respiratory failure often require prolonged mechanical ventilation for two weeks or longer [9].

Regarding the limitations of this study, due to the limited time and resources, thesample size was limited. Furthermore, there are not enough vaccinated patients included in this study. Also, the study did not assess the reason beyond taking or refusing vaccines, so it is highly important to investigate this in the future.

Conclusion

Vaccination is considered an as important tool to reduce the risk of many infectious diseases. Global vaccine development efforts have been accelerated in response to the devastating COVID-19 pandemic. This study found that vaccination against COVID-19 is effective and can lead to positive outcomes. In addition, this study found that an altered consciousness level and the need for oxygen or mechanical ventilation are significantly associated with death.

Atalfadil et al., 2024

Pharmacophore, 15(1) 2024, Pages 36-40

Recommendations

According to the results of this study, it is important to ensure vaccine availability around the country to cover more people.

- To raise awareness among the general population regarding the importance of vaccination against COVID-19.
- To conduct further studies with a larger sample size to determine the vaccinationstatus among COVID-19-positive cases admitted in isolation centers.

Acknowledgments: The authors would like to thank all those who participated and supported this research project.

Conflict of interest: None

Financial support: None

Ethics statement: Ethical approval was obtained from the Sudan Medical Specialization Board (SMSB) (NO, 45/2022), the ethical committee at the research unit EDC, the Ministry of Health, and the administration of the targeted hospitals.

Written informed consent was taken from administrators of the hospital and all patients before participating in the study.

References

- World Health Organization. Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness (Revised March 2022). World Health Organization. 2022. Available from: https://www.who.int/news/item/17-05-2022-statement-for-healthcare-professionals-how-covid-19-vaccines-are-regulated-for-safety- and-effectiveness.
- 2. AbdelMassih AF, Menshawey R, Ismail JH, Husseiny RJ, Husseiny YM, Yacoub S, et al. PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: A review of literature. J Genet Eng Biotechnol. 2021;19(1):82.
- 3. World Health Organization. Vaccine efficacy, effectiveness and protection. 2022. Available from: https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy- effectiveness-and-protection.
- 4. Muthukrishnan J, Vardhan V, Mangalesh S, Koley M, Shankar S, Yadav AK, et al. Vaccination status and COVID-19 related mortality: A hospital based cross sectional study. Med J Armed Forces India. 2021;77:S278-82. doi:10.1016/j.mjafi.2021.06.034
- 5. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386(4):340-50.
- 6. Boehme AK, Doyle K, Thakur KT, Roh D, Park S, Agarwal S, et al. Disorders of consciousness in hospitalized patients with COVID-19: The role of the systemic inflammatory response syndrome. Neurocritical Care. 2022;36(1):89-96.
- 7. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv. 2021:2020.11.27.20240051. doi:10.1101/2020.11.27.20240051
- 8. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. BMJ. 2021;373:n1088. doi:10.1136/bmj.n1088
- 9. De Salazar PM, Link N, Lamarca K, Santillana M. High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in long-term care facilities. Res Sq. 2021:rs.3.rs-355257. doi:10.21203/rs.3.rs-355257/v1